In this article
AMC Opens First Dedicated CAR-T Cell Treatment Center in South Korea
Jan 2023: The Asan Medical Center (AMC) opened the first CAR-T cell treatment facility in the country after the government approved health insurance benefits for Kymriah’s CAR-T cell therapy.
AMC announced on Tuesday that its cancer hospital had opened a CAR-T facility and had started paying for Kymriah treatments that had been approved by Novartis.
How CAR-T Therapy Targets Cancer Cells
In CAR-T therapy, immune cells (T cells) from the patient are removed and transfected with chimeric antigen receptors that target particular cancer cells. The patient is then given an injection of T cells to eradicate the cancer cells.
When treating patients with relapsed and refractory B-cell acute lymphoblastic leukaemia (ALL) who are 25 years of age or younger as well as individuals with refractory diffuse large B-cell lymphoma, Kymriah is covered by insurance (DLBCL).
Relapsed and refractory B-cell ALL and relapsed and refractory DLBCL have been extremely challenging to treat thus far, with the majority of these patients barely living for six months following diagnosis.
According to statistics, CAR-T treatment kills cancer in 50% of adult patients with relapsed and refractory DLBCL and roughly 80% of paediatric patients with relapsed and refractory B-cell ALL.
Insurance Coverage and Efficacy Statistics
Only adult patients will be seen at the AMC’s CAR-T facility by the oncologists Yoon Dok-hyun, Cho Hyung-woo, and the haematologists Lee Jung-hee and Park Han-seung.
Im Ho-joon, Koh Kyung-nam, Kim Hye-ry, and Kang Sung-han, paediatric hemato-oncologists, will provide care for young patients.
Yoon Dok-hyun, the director of the AMC’s CAR-T centre, stated that although CAR-T therapy has a very dramatic effect, it may also result in negative side effects. The first interdisciplinary clinic for CAR-T treatment has been developed by AMC’s CAR-T centre in collaboration with numerous departments, including intensive care unit, neurology, and infectious disease, to build protocols to detect side effects early and provide safe treatment.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Sai Sree
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.